General Information of Drug (ID: DMS0P5O)

Drug Name
MB-103 Drug Info
Indication
Disease Entry ICD 11 Status REF
Glioblastoma multiforme 2A00.0 Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMS0P5O

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Erbb2 tyrosine kinase receptor (HER2) TT6EO5L ERBB2_HUMAN Not Available [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Erbb2 tyrosine kinase receptor (HER2) DTT ERBB2 6.226 7.169 7.196 6.397
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Glioblastoma multiforme
ICD Disease Classification 2A00.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Erbb2 tyrosine kinase receptor (HER2) DTT ERBB2 5.67E-03 -1.26 -2.05
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT03696030) HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of Mustang Bio.